Floxuridine
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | FUDR | — | 1970-12-18 | fda.gov ↗ |
Trials 52 · a red edge is where a trial was stopped
Also used as a comparator or background therapy in 9 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00008294 Background | Aug 2000 → May 2006 | colorectal cancer, metastatic malignant neoplasm | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01692704 Background | Apr 2012 → Mar 2016 | cholangiocarcinoma | University of Zurich | Completed | No outcome recorded |
| Phase 26 trials | ||||||
| Phase 2 | NCT06313203 Comparator | Feb 2024 → Jan 2031 expected | chemotherapy-induced toxicity, intrahepatic cholangiocarcinoma | Oslo University Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT05286814 Background | Oct 2022 → Dec 2027 expected | adrenal cortex carcinoma, colorectal cancer, intrahepatic cholangiocarcinoma | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 2 | NCT05139095 Background | Jan 2022 → Dec 2026 expected | gestational trophoblastic neoplasm | Peking Union Medical College Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT04898504 Comparator | Aug 2021 → May 2025 overdue | metastasis from malignant tumor of colon | Oslo University Hospital | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04668976 Background | Nov 2020 → Dec 2023 | cholangiocarcinoma, colorectal cancer | Benaroya Research Institute | Unknown | No outcome recorded |
| Phase 2 | NCT03693807 Background | Oct 2018 → Jun 2024 | cholangiocarcinoma, colorectal cancer | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00020501 Background | Mar 2001 → Jan 2005 | colorectal cancer, metastatic malignant neoplasm | National Institutes of Health Clinical Center (CC) | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 65 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Floxuridine | “0.12 mg/kg/day floxuridine (FUDR) and 25 mg dexamethasone in normal saline to a total volume of 300 ml will be administered through the HAI pump” NCT02102789 ↗55“HAIP will be filled with mixture of Floxuridine and Dexamethasone.” NCT03366155 ↗ “FAEV \[floxuridine, actinomycin-D, etoposide, vincristine\]” NCT05139095 ↗ “Exemestane, Floxuridine, Fludarabine” NCT02788201 ↗ |
| Known as | Floxuridin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06888063 ↗ |
| Known as | floxuridine (FUDR) | “floxuridine (FUDR)” NCT02102789 ↗ |
| Known as | fluorodeoxyuridine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00001449 ↗ |
| Known as | FUDR | “PHASE III STUDY OF HEPATIC ARTERY FLOXURIDINE (FUDR), LEUCOVORIN (LV), AND DEXAMETHASONE (DEX) VERSUS SYSTEMIC 5-FLUOROURACIL (5-FU) AND LEUCOVORIN (LV) AS TREATMENT FOR...” NCT00002716 ↗24“Prior trials have shown that surgery followed by hepatic artery infusion (HAI) of floxuridine (FUDR) alternating with systemic fluorouracil improves survival rates.” PMID 20048179 ↗ Jan 2010 “The intra-abdominal (intraperitoneal) administration of floxuridine (FUDR) is a procedure that we have studied and have determined it is a safe treatment.” NCT00183911 ↗ “Hepatic arterial infusion pump (HAIP) therapy with floxuridine (FUDR) combined with systemic therapy (SYST) could enhance conversion to resectable CRLM” PMID 42143303 ↗ May 2026 “0.12 mg/kg/day floxuridine (FUDR) and 25 mg dexamethasone in normal saline to a total volume of 300 ml will be administered through the HAI pump.” NCT03493061 ↗ “0.12 mg/kg/day floxuridine (FUDR) and 25 mg dexamethasone in normal saline to a total volume of 300 ml will be administered through the HAI pump.” NCT03678428 ↗ “Patients will receive the interventional treatment, which is neoadjuvant HA chemotherapy (FUDR/oxaliplatin delivered via the Hepatic Artery).” NCT05634720 ↗ “Patients will receive infusion of floxuridine (FUDR) and dexamethasone via hepatic artery infusion through the implanted pump” NCT04276090 ↗ “local chemotherapy comprising floxuridine (FUDR) and CF by hepatic arterial infusion (HAI) continuously on days 14-28” NCT00020501 ↗ “We administered TAC(oxaliplatin,FUDR and MMC) 7 days before liver metastasis resection of colorectal cancer.” NCT00874406 ↗ “Hepatic artery infusion of floxuridine (FUDR) via an implantable hepatic artery infusion pump (HAIP)” NCT03366155 ↗ “hepatic arterial infusion of floxuridine (FUDR) and dexamethasone given via an implanted pump” NCT00003753 ↗ “hepatic arterial floxuridine (FUDR) and dexamethasone (Dex) given via an implanted pump” NCT00059930 ↗ “with hepatic arterial infusion (HAI) of floxuridine (FUDR) and dexamethasone (Dex)” PMID 19233901 ↗ Feb 2009 “hepatic arterial infusion of floxuridine (FUDR), 0.2 mg/kg/day” NCT00001576 ↗ “floxuridine (FUDR)/dexamethasone (Dex)” PMID 21677464 ↗ Jun 2011 “floxuridine (FUDR) at 0.15 mg/kg/day” NCT03876574 ↗ “Floxuridine (FUDR) 500mg/d, Day 1-2” NCT02529774 ↗ “NSC-19893 FUDR Floxuridine” NCT00002783 ↗ “Drug: Floxuridine (FUDR)” NCT01862315 ↗ “Drug: Floxuridine (FUDR)” NCT04891289 ↗ “Drug: Floxuridine (FUDR)” NCT03693807 ↗ “Drug: Floxuridine (FUDR)” NCT04668976 ↗ “HAI-floxuridine (FUDR)” NCT04898504 ↗ |
| Known as | NSC-19893 | “NSC-19893 FUDR Floxuridine” NCT00002783 ↗ |
| Route | Other | “hepatic arterial infusion of floxuridine (FUDR), 0.2 mg/kg/day” NCT00001576 ↗ |